Rapid Micro Biosystems (RPID) Competitors

$1.68 +0.01 (+0.60%)

As of 08/21/2026 04:00 PM Eastern

RPID vs. LAB, CDXS, QSI, MXCT, and QTRX

Should you buy Rapid Micro Biosystems stock or one of its competitors? Rapid Micro Biosystems's main competitors and comparable companies include Standard BioTools (LAB), Codexis (CDXS), Quantum-Si (QSI), MaxCyte (MXCT), and Quanterix (QTRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Rapid Micro Biosystems compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Standard BioTools has a net margin of 100.36% compared to Rapid Micro Biosystems' net margin of -145.56%. Standard BioTools' return on equity of -7.57% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	100.36%	-7.57%	-6.14%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

Standard BioTools presently has a consensus price target of $1.35, indicating a potential upside of 101.79%. Rapid Micro Biosystems has a consensus price target of $6.00, indicating a potential upside of 257.14%. Given Rapid Micro Biosystems' stronger consensus rating and higher possible upside, analysts clearly believe Rapid Micro Biosystems is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Rapid Micro Biosystems' average media sentiment score of 1.00 beat Standard BioTools' score of 0.00 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.

Company	Overall Sentiment
Standard BioTools	Neutral
Rapid Micro Biosystems	Positive

Rapid Micro Biosystems has lower revenue, but higher earnings than Standard BioTools. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.08	-$74.90M	$0.22	3.04
Rapid Micro Biosystems	$33.59M	2.51	-$47.12M	-$1.12	N/A

53.7% of Standard BioTools shares are held by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are held by institutional investors. 26.8% of Standard BioTools shares are held by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Standard BioTools has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.44, indicating that its stock price is 44% more volatile than the broader market.

Summary

Standard BioTools beats Rapid Micro Biosystems on 9 of the 15 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Codexis?

Codexis (NASDAQ:CDXS) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends and analyst recommendations.

Codexis has a net margin of -39.55% compared to Rapid Micro Biosystems' net margin of -145.56%. Codexis' return on equity of -74.36% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

Codexis has a beta of 2.54, indicating that its share price is 154% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Codexis currently has a consensus target price of $6.50, suggesting a potential upside of 289.22%. Rapid Micro Biosystems has a consensus target price of $6.00, suggesting a potential upside of 257.14%. Given Codexis' higher possible upside, analysts clearly believe Codexis is more favorable than Rapid Micro Biosystems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Codexis had 5 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 5 mentions for Codexis and 0 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 1.00 beat Codexis' score of -0.05 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.

Company	Overall Sentiment
Codexis	Neutral
Rapid Micro Biosystems	Positive

78.5% of Codexis shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 3.5% of Codexis shares are owned by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Codexis has higher revenue and earnings than Rapid Micro Biosystems. Codexis is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	2.60	-$43.97M	-$0.34	N/A
Rapid Micro Biosystems	$33.59M	2.51	-$47.12M	-$1.12	N/A

Summary

Codexis beats Rapid Micro Biosystems on 11 of the 15 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Quantum-Si?

Quantum-Si (NASDAQ:QSI) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

39.9% of Quantum-Si shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 22.0% of Quantum-Si shares are owned by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Rapid Micro Biosystems has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quantum-Si	$2.44M	74.52	-$101.34M	-$0.46	N/A
Rapid Micro Biosystems	$33.59M	2.51	-$47.12M	-$1.12	N/A

Rapid Micro Biosystems has a net margin of -145.56% compared to Quantum-Si's net margin of -6,138.26%. Quantum-Si's return on equity of -47.12% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quantum-Si	-6,138.26%	-47.12%	-43.18%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

Quantum-Si has a beta of 3.24, suggesting that its stock price is 224% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.44, suggesting that its stock price is 44% more volatile than the broader market.

Quantum-Si currently has a consensus target price of $1.00, indicating a potential upside of 19.76%. Rapid Micro Biosystems has a consensus target price of $6.00, indicating a potential upside of 257.14%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, analysts clearly believe Rapid Micro Biosystems is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Quantum-Si had 13 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 13 mentions for Quantum-Si and 0 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 1.00 beat Quantum-Si's score of 0.78 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.

Company	Overall Sentiment
Quantum-Si	Positive
Rapid Micro Biosystems	Positive

Summary

Rapid Micro Biosystems beats Quantum-Si on 9 of the 16 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, MaxCyte had 2 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 2 mentions for MaxCyte and 0 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 1.00 beat MaxCyte's score of 0.86 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.

Company	Overall Sentiment
MaxCyte	Positive
Rapid Micro Biosystems	Positive

MaxCyte has higher earnings, but lower revenue than Rapid Micro Biosystems. MaxCyte is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	4.31	-$44.63M	-$0.33	N/A
Rapid Micro Biosystems	$33.59M	2.51	-$47.12M	-$1.12	N/A

MaxCyte presently has a consensus price target of $5.00, indicating a potential upside of 262.32%. Rapid Micro Biosystems has a consensus price target of $6.00, indicating a potential upside of 257.14%. Given MaxCyte's higher possible upside, equities analysts plainly believe MaxCyte is more favorable than Rapid Micro Biosystems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by company insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MaxCyte has a net margin of -114.77% compared to Rapid Micro Biosystems' net margin of -145.56%. MaxCyte's return on equity of -18.92% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

MaxCyte has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Summary

MaxCyte beats Rapid Micro Biosystems on 10 of the 16 factors compared between the two stocks.

How does Rapid Micro Biosystems compare to Quanterix?

Quanterix (NASDAQ:QTRX) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Quanterix currently has a consensus target price of $3.00, indicating a potential upside of 0.33%. Rapid Micro Biosystems has a consensus target price of $6.00, indicating a potential upside of 257.14%. Given Rapid Micro Biosystems' stronger consensus rating and higher probable upside, analysts plainly believe Rapid Micro Biosystems is more favorable than Quanterix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quanterix	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Rapid Micro Biosystems	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

86.5% of Quanterix shares are held by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are held by institutional investors. 1.5% of Quanterix shares are held by insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Quanterix had 5 more articles in the media than Rapid Micro Biosystems. MarketBeat recorded 5 mentions for Quanterix and 0 mentions for Rapid Micro Biosystems. Rapid Micro Biosystems' average media sentiment score of 1.00 beat Quanterix's score of -0.14 indicating that Rapid Micro Biosystems is being referred to more favorably in the news media.

Company	Overall Sentiment
Quanterix	Neutral
Rapid Micro Biosystems	Positive

Quanterix has a net margin of -80.25% compared to Rapid Micro Biosystems' net margin of -145.56%. Quanterix's return on equity of -26.09% beat Rapid Micro Biosystems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quanterix	-80.25%	-26.09%	-19.03%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

Rapid Micro Biosystems has lower revenue, but higher earnings than Quanterix. Rapid Micro Biosystems is trading at a lower price-to-earnings ratio than Quanterix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quanterix	$138.90M	1.02	-$107.15M	-$2.63	N/A
Rapid Micro Biosystems	$33.59M	2.51	-$47.12M	-$1.12	N/A

Quanterix has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Rapid Micro Biosystems has a beta of 1.44, suggesting that its share price is 44% more volatile than the broader market.

Summary

Rapid Micro Biosystems beats Quanterix on 9 of the 16 factors compared between the two stocks.

Get Rapid Micro Biosystems News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RPID and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RPID vs. The Competition

Export

Metric	Rapid Micro Biosystems	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.27M	$10.24B	$7.37B	$12.85B
Dividend Yield	N/A	1.46%	2.54%	11.08%
P/E Ratio	-1.50	61.54	272.88	24.24
Price / Sales	2.51	110.30	618.96	99.76
Price / Cash	N/A	27.04	78.62	53.99
Price / Book	4.80	37.34	13.05	6.20
Net Income	-$47.12M	$56.67B	$3.47B	$348.59M
7 Day Performance	N/A	5.24%	2.09%	0.08%
1 Month Performance	-15.58%	9.02%	6.64%	3.88%
1 Year Performance	-41.05%	24.45%	25.02%	16.98%

Rapid Micro Biosystems Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RPID Rapid Micro Biosystems	2.925 of 5 stars	$1.68 +0.6%	$6.00 +257.1%	-41.1%	$84.27M	$33.59M	N/A	200	Positive News
LAB Standard BioTools	2.5241 of 5 stars	$0.66 -3.3%	$1.35 +103.9%	-47.3%	$268.72M	$84.60M	3.01	620	Gap Down
CDXS Codexis	3.1924 of 5 stars	$1.50 -5.7%	$6.50 +333.3%	-42.0%	$170.83M	$70.39M	N/A	250	Analyst Forecast
QSI Quantum-Si	2.1969 of 5 stars	$0.73 -2.2%	$1.00 +37.4%	-26.8%	$161.10M	$2.44M	N/A	150	News Coverage Analyst Revision
MXCT MaxCyte	3.6369 of 5 stars	$1.27 -3.8%	$5.00 +293.7%	-2.8%	$141.40M	$31.05M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RPID) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rapid Micro Biosystems (RPID) Competitors

RPID vs. LAB, CDXS, QSI, MXCT, and QTRX

How does Rapid Micro Biosystems compare to Standard BioTools?

Summary

How does Rapid Micro Biosystems compare to Codexis?

Summary

How does Rapid Micro Biosystems compare to Quantum-Si?

Summary

How does Rapid Micro Biosystems compare to MaxCyte?

Summary

How does Rapid Micro Biosystems compare to Quanterix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPID vs. The Competition

Rapid Micro Biosystems Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rapid Micro Biosystems (RPID) Competitors

RPID vs. LAB, CDXS, QSI, MXCT, and QTRX

How does Rapid Micro Biosystems compare to Standard BioTools?

Is LAB or RPID more profitable?

Do analysts recommend LAB or RPID?

Does the media refer more to LAB or RPID?

Which has preferable earnings & valuation, LAB or RPID?

Do institutionals and insiders believe in LAB or RPID?

Which has more volatility & risk, LAB or RPID?

Summary

How does Rapid Micro Biosystems compare to Codexis?

Is CDXS or RPID more profitable?

Which has more volatility and risk, CDXS or RPID?

Do analysts recommend CDXS or RPID?

Does the media refer more to CDXS or RPID?

Do institutionals & insiders have more ownership in CDXS or RPID?

Which has better earnings & valuation, CDXS or RPID?

Summary

How does Rapid Micro Biosystems compare to Quantum-Si?

Do insiders and institutionals believe in QSI or RPID?

Which has higher valuation & earnings, QSI or RPID?

Is QSI or RPID more profitable?

Which has more volatility and risk, QSI or RPID?

Do analysts rate QSI or RPID?

Does the media refer more to QSI or RPID?

Summary

How does Rapid Micro Biosystems compare to MaxCyte?

Does the media refer more to MXCT or RPID?

Which has preferable valuation and earnings, MXCT or RPID?

Do analysts rate MXCT or RPID?

Do institutionals & insiders believe in MXCT or RPID?

Is MXCT or RPID more profitable?

Which has more volatility & risk, MXCT or RPID?

Summary

How does Rapid Micro Biosystems compare to Quanterix?

Do analysts recommend QTRX or RPID?

Do institutionals and insiders believe in QTRX or RPID?

Does the media refer more to QTRX or RPID?

Is QTRX or RPID more profitable?

Which has stronger earnings & valuation, QTRX or RPID?

Which has more risk and volatility, QTRX or RPID?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPID vs. The Competition

Rapid Micro Biosystems Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools